Yan T, Schupp J E, Hwang H S, Wagner M W, Berry S E, Strickfaden S, Veigl M L, Sedwick W D, Boothman D A, Kinsella T J
Department of Radiation Oncology, Ireland Comprehensive Cancer Center/University Hospitals of Cleveland, Cleveland, OH 44106-4942, USA.
Cancer Res. 2001 Nov 15;61(22):8290-7.
Our previous data demonstrated that cells deficient in MutL homologue-1 (MLH1) expression had a reduced and shorter G(2) arrest after high-dose-rate ionizing radiation (IR), suggesting that the mismatch re pair (MMR) system mediates this cell cycle checkpoint. We confirmed this observation using two additional isogenetically matched human MLH1 (hMLH1)-deficient and -proficient human tumor cell systems: human ovarian cancer cells, A2780/CP70, with or without ectopically expressed hMLH1, and human colorectal carcinoma cells, RKO, with or without azacytidine treatment to reexpress hMLH1. We also examined matched MutS homologue-2 (hMSH2)-deficient and -proficient human endometrial carcinoma HEC59 cell lines to determine whether hMSH2, and MMR in general, is involved in IR-related G(2) arrest responses. As in MLH1-deficient cells, cells lacking hMSH2 demonstrated a similarly altered G(2) arrest in response to IR (6 Gy). These differences in IR-induced G(2) arrest between MMR-proficient and -deficient cells were found regardless of whether synchronized cells were irradiated in G(0)/G(1) or S phase, indicating that MMR indeed dramatically affects the G(2)-M checkpoint arrest. However, unlike the MMR-dependent damage tolerance response to 6-thioguanine exposures, no significant difference in the clonogenic survival of MMR-deficient cells compared with MMR-proficient cells was noted after high-dose-rate IR. In an attempt to define the signal transduction mechanisms responsible for MMR-mediated G(2) arrest, we examined the levels of tyrosine 15 phosphorylation of cdc2 (phospho-Tyr15-cdc2), a key regulator of the G(2)-M transition. Increased phospho-Tyr15-cdc2 levels were observed in both MMR-proficient and -deficient cell lines after IR. However, the levels of the phospho-Tyr15-cdc2 rapidly decreased in MMR (hMLH1 or hMSH2)-deficient cell lines at times coincident with progress from the IR-induced G(2) arrest through M phase. Thus, differences in the levels of phospho-Tyr15-cdc2 after high-dose-rate IR correspond temporally with the observed differences in the IR-induced G(2) arrest, suggesting that MMR proteins may exert their effect on IR-induced G(2) arrest by signaling the cdc2 pathway. Although MMR status does not significantly affect the survival of cells after high-dose-rate IR, it seems to regulate the G(2)-M checkpoint and might affect overall mutation rates.
我们之前的数据表明,错配修复蛋白同源物1(MutL homologue-1,MLH1)表达缺陷的细胞在高剂量率电离辐射(IR)后,G2期阻滞减少且持续时间缩短,这表明错配修复(MMR)系统介导了该细胞周期检查点。我们使用另外两个基因同型匹配的人MLH1(hMLH1)缺陷型和野生型人肿瘤细胞系统证实了这一观察结果:人卵巢癌细胞A2780/CP70,分别有无异位表达hMLH1;人结肠癌细胞RKO,分别有无经氮杂胞苷处理以重新表达hMLH1。我们还检测了匹配的错配修复蛋白同源物2(hMSH2)缺陷型和野生型人子宫内膜癌HEC59细胞系,以确定hMSH2以及一般的MMR是否参与IR相关的G2期阻滞反应。与MLH1缺陷细胞一样,缺乏hMSH2的细胞在受到IR(6 Gy)照射后,G2期阻滞也出现了类似的改变。无论同步化细胞是在G0/G1期还是S期接受照射,MMR功能正常和缺陷细胞在IR诱导的G2期阻滞方面都存在这些差异,这表明MMR确实显著影响G2-M期检查点阻滞。然而,与对6-硫鸟嘌呤暴露的MMR依赖的损伤耐受反应不同,在高剂量率IR后,未观察到MMR缺陷细胞与MMR功能正常细胞的克隆形成存活率有显著差异。为了确定负责MMR介导的G2期阻滞的信号转导机制,我们检测了细胞周期蛋白依赖性激酶2(cdc2)酪氨酸15位点的磷酸化水平(磷酸化酪氨酸15-cdc2),它是G2-M期转换的关键调节因子。IR照射后,在MMR功能正常和缺陷的细胞系中均观察到磷酸化酪氨酸15-cdc2水平升高。然而,在MMR(hMLH1或hMSH2)缺陷的细胞系中,磷酸化酪氨酸15-cdc2水平在与从IR诱导的G2期阻滞进入M期同步的时间点迅速下降。因此,高剂量率IR后磷酸化酪氨酸15-cdc2水平的差异在时间上与观察到的IR诱导的G2期阻滞差异相对应,这表明MMR蛋白可能通过向cdc2信号通路发出信号来对IR诱导的G2期阻滞发挥作用。虽然MMR状态在高剂量率IR后对细胞存活没有显著影响,但它似乎调节G2-M期检查点,并且可能影响总体突变率。